Non-calcified Plaque Research Articles

Low-density Non-calcified Plaque Burden Derived From Artificial Intelligence-guided CCTA Quantification Is Associated With 1-year Cardiovascular Outcomes

Low-density Non-calcified Plaque Burden Derived From Artificial Intelligence-guided CCTA Quantification Is Associated With 1-year Cardiovascular Outcomes

Low-intensity extracorporeal shockwave therapy for Peyronie's disease: An Indian experience.

Efficacy of low-intensity extracorporeal shockwave therapy (LiESWT) in Peyronie's disease (PD) has not been studied in an Indian population. Here, we studied the effect of LiESWT in Indian PD patients. This prospective study was conducted on 25 patients who completed weekly sessions of LiESWT for 6 weeks with a follow-up of 6 months. Patients were evaluated using International Index of Erectile Function (IIEF)-5 questionnaire for erectile dysfunction and visual analog scale for pain. Baseline and follow-up examinations included measurement of plaque size and curvature. The primary outcome was to assess remission of pain and reduction of plaque size along with improvement of penile curvature and erectile function as the secondary outcome. Primary goal of pain reduction and ≥50% reduction of plaque size was achieved in 64% and 20% of patients, respectively. Improvement in vaginal penetration during sexual intercourse and IIEF-5 score increase of ≥3 was achieved 20% and 36% cases, respectively. The mean reduction of penile curvature was more with plaque calcification (PC), but the difference was not statistically significant (P = 0.26). The difference in mean visual analog scale reduction was more in noncalcified plaque (P = 0.002). The mean reduction of plaque size in patients with PC was significant (P = 0.03). Shockwave therapy is a probable alternative treatment option. A significant improvement was observed in pain and plaque size in patients treated by LiESWT. The presence of PC may affect the outcome of LiESWT in PD.

Exploring pericoronary adipose tissue differences between calcified and non-calcified plaques on coronary CT angiography with fat attenuation index and radiomics analysis

Abstract Funding Acknowledgements Type of funding sources: Public grant(s) – National budget only. Main funding source(s): Ministry of Science and Technology. Introduction Coronary CT angiography (CCTA)-derived pericoronary adipose tissue (PCAT) is a novel marker for coronary inflammation. The relationship between the extravascular PCAT and the vascular lesion itself is particularly important to establish its use in monitoring the disease status. Past studies investigated lesion-level PCAT differences in vessels with acute myocardial infarction. However, lesion-level PCAT differences between calcified and non-calcified plaques in patients with stable coronary artery disease were not well understood. Purpose To investigate the differences between PCAT adjacent to calcified and PCAT adjacent to non-calcified plaques using fat attenuation index (FAI) and radiomics analysis. Material and Methods In a cohort of 100 consecutive patients who underwent CCTA, 446 plaques were identified in 89 patients. Among these plaques, 213 were calcified plaques and 49 were non-calcified plaques, with the rest classified as mixed by our expert cardiologist and radiologist. The PCAT of these 262 plaques were then extracted. Following prior literature, adipose tissue was defined as voxels with attenuation ranging −190 to −30 HU. PCAT was extracted within 3 mm distance from the vessel wall, along the middle 10 mm of each plaque. FAI was defined as the mean attenuation of the PCAT volume. For radiomics analysis, we used PyRadiomics to calculate the radiomic features and the random forest classifier from Scikit-Learn to distinguish PCAT volumes of calcified and non-calcified plaques. Patient-level 5-fold cross validation was used to develop the classifier. Result FAI were higher in PCAT adjacent to non-calcified plaques compared to PCAT adjacent to calcified plaques (−81.4 [IQR: −91.8 to −73.5] vs −86.7 [IQR: −94.1 to −78.4], p = 0.008). The classifier using radiomics features achieved better discrimination (AUROC=0.738 [0.715–0.761]) than FAI alone (AUROC=0.607 [0.605–0.609]). Conclusion Significant differences in PCAT characteristics were found between calcified and non-calcified plaques either with direct comparison of FAI or radiomics analysis. Radiomics analysis revealed further discrimination between PCAT characteristics other than FAI may exist between calcified and non-calcified plaques. It is also important to note that the FAI of calcified plaques could be affected by beam hardening. Further investigation is needed to explore the underlying cause of such differences and their clinical implications.

Changes in coronary plaque component volumes comparing different virtual monoenergetic images using photon-counting computed tomography

Abstract Funding Acknowledgements Type of funding sources: Public grant(s) – National budget only. Main funding source(s): BV was supported by the ÚNKP-22-3-II-SE New National Excellence Program of the Ministry for Culture and Innovation from the source of the National Research, Development and Innovation Fund. Introduction Photon-counting CT (PCCT) allows virtual monoenergetic images (VMIs) which may aid more precise assessment of coronary plaques. We aimed to analyze how plaque component volumes change on different VMIs. Methods Coronary CT angiography images were acquired using a dual-source PCCT and VMIs were reconstructed between 40–180 keV in 10 keV increments. Polychromatic images at 120 kVp (T3D) were also reconstructed and used as reference. Quantitative image quality analysis was performed on all reconstructed images. Quantitative plaque assessment was performed on T3D images and segmentation masks were copied to all VMI images. Calcified plaque (CP; >350 Hounsfield units, HU), non-calcified plaque (NCP; 30–350HU) and low-attenuation NCP (LAP; −100-30HU) volumes were calculated. Results We analyzed 51 plaques from 51 patients (67% male, mean age 65±12 years). Average attenuation and contrast-to-noise ratio (CNR) decreased significantly with increasing keV levels, with similar values observed between T3D and 70 keV images (299±209 vs 303±225 HU, p = 0.15 for mean HU; 15.5±3.7 vs. 15.8±3.5, p = 0.32 for CNR). Mean NCP volume was comparable between T3D and 100–180 keV reconstructions. There was a graded decrease in mean CP volume, with a significant difference between all VMI images and T3D (p<0.05). LAP volume increased with increasing VMI energy levels and all VMI images showed a significant difference compared to T3D, except for 50 keV (28.0±30.8 mm3 and 28.6±30.1 mm3, respectively, p = 0.63). Conclusion Fixed threshold settings result in significantly different plaque volumes when using VMIs as compared to T3D images. Normalization protocols are needed to have comparable results between future studies.

Body mass components affecting low-attenuation noncalcified coronary plaque burden

Abstract Funding Acknowledgements Type of funding sources: Public hospital(s). Main funding source(s): National Institute of Cardiology in Warsaw, Poland Background Weight control is a major risk modifier for coronary artery disease. However, the effect exerted by individual body mass components on coronary plaque may not be uniform. Low-attenuation noncalcified plaque (LAP) has been recently identified as an independent predictor of cardiovascular outcomes [1]. Purpose To determine the relationship between changes in body mass composition and LAP burden. Methods 89 participants of Dietary Intervention to Stop Coronary Atherosclerosis in Computed Tomography (DISCO-CT) were enrolled into the analysis (40% women, mean age 60±7.7 years). Patients with non-obstructive (stenosis<70%) coronary atherosclerosis confirmed in coronary computed tomography angiography (CCTA) and qualified to conservative treatment were randomized (1:1) to intensive diet and lifestyle intervention atop optimal medical therapy (OMT) versus OMT alone over 66.8±13.7 months [2]. Body mass (BM) and body mass components including total body fat (TBF), skeletal muscle mass (SMM), visceral cell mass (VCM), and extracellular mass (ECM) were measured at baseline and follow-up (InBody S10 analyser, South Korea). LAP burden was defined as the volume of coronary plaque <30 Hounsfield units divided by the vessel volume, and expressed in %. Changes in body components were compared with changes in LAP measured in serial CCTA scans (QAngioCT, Medis Medical Imaging Systems, the Netherlands). Results Reduction in BM was significantly higher in the experimental (∆BM=-3.6±4.9 kg) vs control arm (∆BM=-1.4±2.9 kg; p = 0.016) and so was the reduction in TBF (∆TBF=-4.2±5.3 kg vs ∆TBF=0.2±4.3 kg, respectively; p<0.001). SMM increased by 0.4±2.6 kg in the experimental arm and decreased by 1.0±2.1 kg in the control arm (p = 0.006). No significant interarm differences were observed for changes in VCM and ECM. Reduction in LAP was higher in the experimental vs control arm (∆LAP=-0.42±1.4% vs ∆LAP=-0.03±0.45%, respectively; p = 0.078). In the entire study population, a significant positive correlation between LAP reduction and BM reduction was revealed (r=0.45, p<0.001). Multivariate regression model incorporating the investigated body mass components identified TBF as the only component associated with LAP reduction (table). Conclusions Body mass reduction may decrease LAP burden due to body fat reduction.

Progression of atherosclerotic plaque determined by computed tomography angiography: a practical CCTA-based SCORE

Abstract Funding Acknowledgements Type of funding sources: None. Background Currently, no recommendations are endorsed by the different scientific societies on the clinical use of repeated coronary computed tomography angiography (CCTA) in patients with non-obstructive coronary artery disease (CAD). Purpose The aim of this study was to develop and validate a practical and simple CCTA risk score to predict medium-term disease progression in symptomatic patients at low-to-intermediate probability of CAD. Methods Six hundred forty-six [430 (derivation cohort) and 216 (validation cohort)] symptomatic patients with two repeated, clinically indicated CCTA scans, non-obstructive stenosis, and absence of high-risk plaque at baseline CCTA were included. Disease progression was defined as the new occurrence of obstructive CAD (stenosis≥50%) and/or high-risk plaque features at follow-up CCTA. Results In the derivation cohort a total of 167 (27%) patients experienced disease progression. Hazard ratios for disease progression derived from multivariable Cox proportional hazard model were as follows: 1.8 (95% confidence interval: 1.1–2.8) for active smoking, 1.2 (1.1–1.3) for segment involvement score, 0.45 (0.29–0.69) for calcified plaque (vs. non-calcified plaque), 2.7 (1.8–4.0) for stenosis 25–49% (vs. stenosis <25%), and 1.6 (1.1–2.4) for left main or proximal left anterior descending coronary artery location. The C-statistic of the derived score was 0.69 (0.63–0.74) and 0.62 (0.54–0.71) in the derivation and validation cohorts, respectively. Figure shows 2 explicative cases. Conclusions The new CCTA-based risk score is a simple and practical tool which can predict mid-term CAD progression in symptomatic patients with non-obstructive CAD.

Are artificial intelligence derived coronary atherosclerotic characteristics associated with subsequent development of acute coronary syndrome (ACS)

Abstract Funding Acknowledgements Type of funding sources: Public hospital(s). Main funding source(s): Scripps Health Krueger Wyeth Grant Background ACS results from unstable atherosclerotic plaques. Current measures to assess risk do not consider the patient’s coronary atherosclerotic composition. This was a case control study using a prospective single-center registry of patients undergoing CCTA (N=2,700) from 2017–2020 to assess the association between plaque characterization and the occurrence of ACS. Methods ACS cases were adjudicated independently by two cardiologists using data from the EMR. Patients with prior ACS prior to CCTA, were excluded. Controls were selected 1:1 by nearest neighbor propensity matching (R. v. 4.0.3.) based on age, sex, smoking, HTN, HLD, and DM. Plaque burden and stenosis features were calculated by a commercially available artificial intelligence (AI) coronary analysis (Figure 1). Results There were 21 cases and 21 controls. Mean age of 68, 43% women, 5% Hispanic, 29% smoking hx, 76% HTN, 81% HLD, 24% DM, CAD-RADS score 2.3, and CAC of 487. Median time from CT to ACS for cases was 329 days. Presence of total non-calcified plaque, calcified plaque, fibro-fatty plaque, maximum stenosis diameter percentage and total plaque were each associated with greater risk of ACS (Table 1). Conclusion AI assessment of CCTA plaque characteristics were associated with ACS. This study shows the association between AI derived coronary atherosclerotic features and development of ACS in patients undergoing CCTA and highlights the potential utility of using AI-driven plaque characterization to predict ACS.

Impact of left coronary artery bifurcation angle on computed tomography derived fractional flow reserve in normal coronary artery disease

Abstract Funding Acknowledgements Type of funding sources: None. Background Computed-tomography (CT) derived fractional-flow-reserve (FFRCT) decreases from the proximal to the distal part of vessel due to the influence of various factors. The energy loss due to the bifurcation angle may potentially contribute to a progressive FFRCT decline. However, the association of the bifurcation angle with FFRCT is still not entirely understood. Purpose This study aimed to investigate the impact of various bifurcation angles on FFRCT decline below the clinically crucial pathological value of 0.80 in normal coronary arteries. Methods A total of 83 consecutive patients who underwent both CT angiography including FFRCT and invasive coronary angiography, resulting in normal coronary arteries were evaluated. ΔFFRCT was defined as the magnitude of the change in FFRCT from the proximal to the distal vessel in the left anterior descending (LAD) and left circumflex (LCX). Both LAD angle and LCX bifurcation angle were measured as the crossing angle between the centrelines of the left main trunk and each coronary artery (LAD or LCX) on the 3-dimensional volume rendered image of the coronary artery tree (Figure 1). Vessel length, lumen volume, non-calcified plaque volume, and calcified plaque volume were assessed. Results Bifurcation angle was significantly lower in LAD angle (LAD angle, 31.1 ± 6.6°; LCX angle, 42.8 ± 14.9°, p < 0.0001). FFRCT showed a continuous gradual decline from the proximal to the distal in both LAD (from 0.95 ± 0.03 to 0.81 ± 0.06) and LCX (from 0.96 ± 0.03 to 0.88 ± 0.06). ΔFFRCT was significantly greater in LAD angle (LAD angle, 0.13 ± 0.06; LCX angle, 0.08 ± 0.05, p < 0.0001) ΔFFRCT was significantly correlated with each bifurcation angle (LAD angle, r = 0.35, p = 0.001; LCX angle, r = 0.26, p = 0.02) and vessel length (LAD angle, r = 0.30, p = 0.005; LCX angle, r = 0.49, p < 0.0001) (Figure 2A). In LAD, vessel length was the strongest predictor for distal FFRCT of ≤ 0.80 (β-coefficient = 0.56, p = 0.0002), immediately followed by the bifurcation angle (β-coefficient = 0.24, p = 0.02). The bifurcation angle was a good predictor for a distal FFRCT ≤ 0.80 (LAD angle, cut-off 31.0°, AUC 0.70, 95% CI 0.58–0.83, sensitivity 74%, specificity 68%; LCX angle, cut-off 52.6°, AUC 0.86, 95% CI 0.76–0.96, sensitivity 88%, specificity 85%) (Figure 2B). Conclusions The change in FFRCT depended on the bifurcation angle. In normal coronary arteries, vessel length was the most influential factor on FFRCT, immediately followed by the bifurcation angle.

Value of fractional flow reserve derived from coronary computed tomographic angiography and plaque quantitative analysis in predicting adverse outcomes of non-obstructive coronary heart disease

To investigate the value of coronary computed tomographic angiography (CCTA)-based fractional flow reserve (CT-FFR) and plaque quantitative analysis in predicting adverse outcomes in patients with non-obstructive coronary heart disease (CAD). Clinical data of patients with non-obstructive CAD who underwent CCTA at the Affiliated Hospital of Jiangnan University from March 2014 to March 2018 were retrospectively analyzed and followed up, and the occurrence of major adverse cardiovascular event (MACE) was recorded. The patients were divided into MACE and non-MACE groups according to the occurrence of MACE. The clinical data, CCTA plaque characteristics including plaque length, stenosis degree, minimum lumen area, total plaque volume, non-calcified plaque volume, calcified plaque volume, plaque burden (PB) and remodelling index (RI), and CT-FFR were compared between the two groups. Multivaritate Cox proportional risk model was used to evaluate the relationship between clinical factors, CCTA parameters and MACE. The receiver operator characteristic curve (ROC curve) was used to assess the predictive power of outcome prediction model based on different CCTA parameters. Finally 217 patients were included, of which 43 (19.8%) had MACE and 174 (80.2%) did not. The median follow-up interval was 24 (16, 30) months. The CCTA showed that patients in the MACE group had more severe stenosis than that in the non-MACE group [(44.3±3.8)% vs. (39.5±2.5)%], larger total plaque volume and non-calcified plaque volume [total plaque volume (mm3): 275.1 (197.1, 376.9), non-calcified plaque volume (mm3): 161.5 (114.5, 307.8) vs. 117.9 (77.7, 185.5)], PB and RI were larger [PB: 50.2% (42.1%, 54.8%) vs. 45.1% (38.2%, 51.7%), RI: 1.19 (0.93, 1.29) vs. 1.03 (0.90, 1.22)], CT-FFR value was lower [0.85 (0.80, 0.88) vs. 0.92 (0.87, 0.97)], and the differences were statistically significant (all P < 0.05). Cox regression analysis showed that non-calcified plaques volume [hazard ratio (HR) = 1.005. 95% confidence interval (95%CI) was 1.025-4.866], PB ≥ 50% (HR = 3.146, 95%CI was 1.443-6.906), RI ≥ 1.10 (HR = 2.223, 95%CI was 1.002-1.009) and CT-FFR ≤ 0.87 (HR = 2.615, 95%CI was 1.016-6.732) were independent predictors of MACE (all P < 0.05). The model based on CCTA stenosis degree+CT-FFR+quantitative plaque characteristics (including non-calcified plaque volume, RI, PB) [area under the ROC curve (AUC) = 0.91, 95%CI was 0.87-0.95] had significantly better predictive efficacy for adverse outcomes than the model based on CCTA stenosis degree (AUC = 0.63, 95%CI was 0.54-0.71) and the model based on CCTA stenosis degree+CT-FFR (AUC = 0.71, 95%CI was 0.63-0.79; both P < 0.01). CT-FFR and plaque quantitative analysis based on CCTA are helpful in predicting adverse outcomes in patients with non-obstructive CAD. Non-calcified plaque volume, RI, PB and CT-FFR are important predictors of MACE. Compared with the prediction model based on stenosis degree and CT-FFR, the combined plaque quantitative index can significantly improve the prediction efficiency of adverse outcomes in patients with non-obstructive CAD.

Advanced glycation endproducts and dicarbonyl compounds are not associated with coronary atherosclerosis characteristics in middle-aged and older male athletes

Abstract Funding Acknowledgements Type of funding sources: Foundation. Main funding source(s): Dutch Heart Foundation. Background Cardiovascular disease is the leading cause of mortality worldwide and is dominated by coronary atherosclerosis. Moreover, coronary atherosclerosis is the most common cause of sudden cardiac death among athletes and current screening methods lack sufficient accuracy for identifying individuals at high risk. Advanced glycemic end products (AGEs) and dicarbonyl stress markers are generated during normal metabolism and aging, but increase in the presence of hyperglycemia, oxidative stress and inflammation. Several studies have demonstrated that higher concentrations of AGEs in plasma predict both the presence and severity of coronary atherosclerosis, as well as mortality. AGEs and its dicarbonyl precursors in atherosclerotic plaques have also been demonstrated to predict rupture-prone phenotypes. Plasma AGEs and dicarbonyl precursors might be a novel way to screen for high-risk coronary atherosclerosis in middle-aged and older athletes. Purpose To assess the association between plasma AGEs and dicarbonyl compounds with the presence of coronary plaques, plaque characteristics and coronary artery calcification scores in a population of middle-aged and older amateur athletes. Methods We measured concentrations of AGEs and dicarbonyl stress markers in plasma with dilution ultra-performance liquid chromatography tandem mass spectrometry in middle-aged and older athletes from the Measuring Athletes’ Risk of Cardiovascular Events (MARC) 2 study cohort. Coronary plaques, predominating plaque characteristics (&amp;gt;50% calcified, non-calcified, or mixed plaque composition), and coronary artery calcification scores were assessed using coronary computed tomography. We explored associations with linear and logistic regression analyses and compared groups with the Mann-Whitney U and Kruskal-Wallis tests, while correcting for multiple testing. Results 284 men were included with a median age of 60 [56-66] years, body mass index of 24.5 [22.9-26.7] kg/m2, and an average weekly exercise volume of 41 [26-57] Metabolic Equivalent of Task-hours. Coronary plaques were detected in 241 participants (83%), with calcified, non-calcified, and mixed plaques constituting &amp;gt;50% of plaques in 42%, 12%, and 21%, respectively. Median CAC score was 31 [0-132]. None of the AGEs or dicarbonyl stress markers were associated with presence of plaques, any of the plaque characteristics (Figure 1), or coronary artery calcification score categories (Figure 2) in adjusted analyses (P&amp;gt;0.05). Conclusion Concentrations of AGEs and dicarbonyl stress markers could not be used to identify coronary plaques, different plaque characteristics or coronary calcifications in this cohort of middle-aged and older athletes. These findings suggest that AGEs and dicarbonyl stress markers cannot be used as a screening method for high-risk coronary atherosclerosis.

Evolocumab attenuate pericoronary adipose tissue density via reduction of lipoprotein(a) in type 2 diabetes mellitus: a serial follow-up CCTA study

BackgroundPericoronary adipose tissue (PCAT) density is a biomarker of vessel inflammation, which is supposed to be increased in patients with type 2 diabetes mellitus (T2DM). However, whether the coronary inflammation revealed by this novel index could be alleviated after evolocumab treatment in T2DM remains unknown.MethodsFrom January 2020 to December 2022, consecutive T2DM patients with low-density lipoprotein cholesterol ≥ 70 mg/dL on maximally tolerated statin and taking evolocumab were prospectively included. In addition, patients with T2DM who were taking statin alone were recruited as control group. The eligible patients underwent baseline and follow-up coronary CT angiography with an interval of 48-week. To render patients with evolocumab as comparable to those controls, a propensity-score matching design was used to select the matched pairs with a 1:1 ratio. Obstructive lesion was defined as the extent of coronary artery stenosis ≥ 50%; the numbers inside the brackets were interquartile ranges.ResultsA total of 170 T2DM patients with stable chest pain were included [(mean age 64 ± 10.6 [range 40–85] years; 131 men). Among those patients, 85 were in evolocumab group and 85 were in control group. During follow-up, low-density lipoprotein cholesterol (LDL-C) level (2.02 [1.26, 2.78] vs. 3.34 [2.53, 4.14], p < 0.001), and lipoprotein(a) (12.1 [5.6, 21.8] vs. 18.9 [13.2, 27.2], p = 0.002) were reduced after evolocumab treatment. The prevalence of obstructive lesions and high-risk plaque features were significantly decreased (p < 0.05 for all). Furthermore, the calcified plaque volume were significantly increased (188.3 [115.7, 361.0] vs. 129.3 [59.5, 238.3], p = 0.015), while the noncalcified plaque volume and necrotic volume were diminished (107.5 [40.6, 180.6] vs. 125.0 [65.3, 269.7], p = 0.038; 0 [0, 4.7] vs. 0 [0, 13.4], p < 0.001, respectively). In addition, PCAT density of right coronary artery was significantly attenuated in evolocumab group (− 85.0 [− 89.0, − 82.0] vs. − 79.0 [− 83.5, − 74.0], p < 0.001). The change in the calcified plaque volume inversely correlated with achieved LDL-C level (r = − 0.31, p < 0.001) and lipoprotein(a) level (r = − 0.33, p < 0.001). Both the changes of noncalcified plaque volume and necrotic volume were positively correlated with achieved LDL-C level and Lp(a) (p < 0.001 for all). However, the change of PCATRCA density only positively correlated with achieved lipoprotein(a) level (r = 0.51, p < 0.001). Causal mediation analysis revealed Lp(a) level mediated 69.8% (p < 0.001) for the relationship between evolocumab and changes of PCATRCA.ConclusionsIn patients with T2DM, evolocumab is an effective therapy to decrease noncalcified plaque volume necrotic volume, and increase calcified plaque volume. Furthermore, evolocumab could attenuate PCAT density, at least in part, via the reduction of lipoprotein(a).

Predictive value of DEEPVESSEL-fractional flow reserve and quantitative plaque analysis based on coronary CT angiography for major adverse cardiac events

To investigate the predictive value of the combination of DEEPVESSEL-fractional flow reserve (DVFFR) and quantitative plaque analysis using coronary computed tomographic angiography (CCTA) for major adverse cardiac events (MACE). In this retrospective study, data from 69 vessels from 58 consecutive patients were collected. These patients who underwent coronary angiography (CAG) with DVFFR were divided into MACE-positive and MACE-negative groups. DVFFR measurements were obtained from CCTA images acquired before CAG, and an FFR or DVFFR value≤0.80 was considered haemodynamically significant. CCTA images were analysed quantitatively using automated software to obtain the following indices: total plaque volume (TPV) and burden (TPB), calcified plaque volume (CPV) and burden (CPB), non-calcified plaque volume (NCPV) and burden (NCPB), low-attenuation plaque (LAP), minimum lumen area (MLA), stenosis grade (SG) and lesion length (LL). Univariate and multivariate logistic regression, correlation, and receiver operating characteristic (ROC) analyses were used for statistical analysis. DVFFR was highly correlated with invasive FFR (R=0.728), and the Bland-Altman plot showed good agreement between DVFFR and FFR (95% CI: -0.109-0.087) on a per-vessel level. DVFFR showed a high diagnostic performance in identifying abnormal haemodynamic vessels, with an area under the ROC curve (AUC) of 0.984. In multivariate analysis, the following biomarkers were predictors of MACE: DVFFR ≤ 0.8, SG, TPB, NCPB, and LL values. The combination of the above independent risk factors yielded the most valuable prediction for MACE (AUC:0.888). DVFFR was highly correlated with FFR with satisfactory diagnostic accuracy. DVFFR, together with plaque analysis indices, yielded valuable predictions for MACE.

Latent Coronary Plaque Morphology From Computed Tomography Angiography, Molecular Disease Activity on Positron Emission Tomography, and Clinical Outcomes.

Assessments of coronary disease activity with 18F-sodium fluoride positron emission tomography and radiomics-based precision coronary plaque phenotyping derived from coronary computed tomography angiography may enhance risk stratification in patients with coronary artery disease. We sought to investigate whether the prognostic information provided by these 2 approaches is complementary in the prediction of myocardial infarction. Patients with known coronary artery disease underwent coronary 18F-sodium fluoride positron emission tomography and coronary computed tomography angiography on a hybrid positron emission tomography/computed tomography scanner. Coronary 18F-NaF uptake was determined by the coronary microcalcification activity. We performed quantitative plaque analysis of coronary computed tomography angiography datasets and extracted 1103 radiomic features for each plaque. Using weighted correlation network analysis, we derived latent morphological features of coronary lesions which were aggregated to patient-level radiomics nomograms to predict myocardial infarction. Among 260 patients with established coronary artery disease (age, 65±9 years; 83% men), 179 (69%) participants showed increased coronary 18F-NaF activity (coronary microcalcification activity>0). Over 53 (40-59) months of follow-up, 18 patients had a myocardial infarction. Using weighted correlation network analysis, we derived 15 distinct eigen radiomic features representing latent morphological coronary plaque patterns in an unsupervised fashion. Following adjustments for calcified, noncalcified, and low-density noncalcified plaque volumes and 18F-NaF coronary microcalcification activity, 4 radiomic features remained independent predictors of myocardial infarction (hazard ratio, 1.46 [95% CI, 1.03-2.08]; P=0.03; hazard ratio, 1.62 [95% CI, 1.04-2.54]; P=0.02; hazard ratio, 1.49 [95% CI, 1.07-2.06]; P=0.01; and hazard ratio, 1.50 (95% CI, 1.05-2.13); P=0.02). In patients with established coronary artery disease, latent coronary plaque morphological features, quantitative plaque volumes, and disease activity on 18F-sodium fluoride positron emission tomography are additive predictors of myocardial infarction.

Correlation of pericoronary adipose tissue CT attenuation values of plaques and periplaques with plaque characteristics

•The PCATP and PCATPP CT attenuation values were higher in NCPs and MPs than CPs. •The PCATP and PCATPP CT attenuation values were higher in DS plaques than PS and MS. •PCATP and PCATPP CT attenuation values correlated with plaque type and location. Aim To investigate the relationship between different plaque characteristics and pericoronary adipose tissue (PCAT) computed tomography (CT) attenuation values for plaques and periplaques. Materials and methods The data from 188 eligible patients with stable coronary heart disease (280 lesions) who underwent coronary CT angiography between March 2021 and November 2021 were collected retrospectively. All PCAT CT attenuation values of plaques and periplaques (the area within 5 and 10 mm proximal and distal to the plaque) were calculated, and multiple linear regression was used to assess their correlation with different plaque characteristics. Results PCAT CT attenuation of plaques and periplaques was higher in non-calcified plaques (–73.38 ± 10.41 HU, –76.77 ± 10.86 HU, 79.33 ± 11.13 HU, –75.67 ± 11.24 HU, –78.63 ± 12.09 HU) and mixed plaques (–76.83 ± 8.11 HU, –79 [–85, –68.5] HU, –78.55 ± 11 HU, –78.76 ± 9.9 HU, –78.79 ± 11.06 HU) than in calcified plaques (–86.96 ± 10 HU, –84 [–92, –76] HU, –84.14 ± 11.08 HU, –84.91 ± 11.41 HU, –84.59 ± 11.69 HU; all p<0.05) and higher in distal segment plaques than in proximal segment plaques (all p<0.05). Plaque PCAT CT attenuation was lower in plaques with minimal stenosis than in plaques with mild or moderate stenosis (p<0.05). The significant determinants of PCAT CT attenuation values of plaques and periplaques were non-calcified plaques, mixed plaques, and plaques located in the distal segment (all p<0.05). Conclusions PCAT CT attenuation values in both plaques and periplaques were related to plaque type and location. To investigate the relationship between different plaque characteristics and pericoronary adipose tissue (PCAT) computed tomography (CT) attenuation values for plaques and periplaques. The data from 188 eligible patients with stable coronary heart disease (280 lesions) who underwent coronary CT angiography between March 2021 and November 2021 were collected retrospectively. All PCAT CT attenuation values of plaques and periplaques (the area within 5 and 10 mm proximal and distal to the plaque) were calculated, and multiple linear regression was used to assess their correlation with different plaque characteristics. PCAT CT attenuation of plaques and periplaques was higher in non-calcified plaques (–73.38 ± 10.41 HU, –76.77 ± 10.86 HU, 79.33 ± 11.13 HU, –75.67 ± 11.24 HU, –78.63 ± 12.09 HU) and mixed plaques (–76.83 ± 8.11 HU, –79 [–85, –68.5] HU, –78.55 ± 11 HU, –78.76 ± 9.9 HU, –78.79 ± 11.06 HU) than in calcified plaques (–86.96 ± 10 HU, –84 [–92, –76] HU, –84.14 ± 11.08 HU, –84.91 ± 11.41 HU, –84.59 ± 11.69 HU; all p<0.05) and higher in distal segment plaques than in proximal segment plaques (all p<0.05). Plaque PCAT CT attenuation was lower in plaques with minimal stenosis than in plaques with mild or moderate stenosis (p<0.05). The significant determinants of PCAT CT attenuation values of plaques and periplaques were non-calcified plaques, mixed plaques, and plaques located in the distal segment (all p<0.05). PCAT CT attenuation values in both plaques and periplaques were related to plaque type and location.

A clinical study of the correlation between metabolic-associated fatty liver disease and coronary plaque pattern

Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic syndrome (MetS) and has been correlated with coronary atherosclerosis (CAS). Since NAFLD was renamed metabolic-associated fatty liver disease(MAFLD) in 2020, no studies have evaluated the correlation between MAFLD and CAS. The aim of this study was to evaluate the relationship between MAFLD and CAS. A total of 1330 patients underwent continuous coronary computed tomography angiography (CCTA) and abdominal ultrasound as part of a routine physical examination. Ultrasonography was used to assess fatty liver, and CCTA was used to assess coronary artery plaques, degree of stenosis, and diseased blood vessels. Univariate and multivariate logistic regression analyses were performed with plaque type and degree of stenosis as dependent variables and MAFLD and traditional cardiovascular risk factors as independent variables to analyze the correlation between MAFLD and CAS. Among the 1164 patients, 680 (58.4%) were diagnosed with MAFLD through a combination of ultrasound and auxiliary examinations. Compared with the non-MAFLD group, the MAFLD group had more cardiovascular risk factors,and the MAFLD group had more likely to have coronary atherosclerosis, coronary stenosis and multiple coronary artery stenosis.In the univariate logistic regression, MAFLD was significantly correlated with overall plaque, calcified plaques, noncalcified plaques, mixed plaques,and significant stenosis in the coronary arteries.(p < 0.05). After adjusting for cardiovascular risk factors , MAFLD was correlated with noncalcified plaques (1.67; 95% confidence interval (CI) 1.15–2.43; p = 0.007) and mixed plaques (1.54; 95% CI 1.10–2.16; p = 0.011). In this study, MAFLD group had more cardiovascular risk factors, MAFLD was correlated with coronary atherosclerosis,and significant stenosis.Further study found independent associations between MAFLD and noncalcified plaques and mixed plaques, which suggest a clinically relevant link between MAFLD and coronary atherosclerosis.

Silent Micro-Infarct in Carotid Artery Stenting: Who Has it and Why?

Carotid stenosis (CS) is one of the modifiable risk factors for stroke. We aimed to compare the postprocedural cerebral diffusion-weighted imaging (DWI) findings in cases of CS-related carotid plaques in terms of plaque morphology, degree of stenosis, and the use of a distal protection filter. We also used DWI to assess the asymptomatic cerebral embolism rates during carotid artery stending (CAS) operations performed for noncalcified versus calcified carotid plaques. Our study included 99 patients admitted to the Ankara City Hospital Stroke Center in 2022. All of our patients have been evaluated and scheduled for CAS as a result of a decision made by the council. Cases of stenosis of 50% in symptomatic patients and 70% in asymptomatic patients were included. The patients were grouped according to their Doppler ultrasonography results. All of the patients underwent DWI within the first 24 hours after the procedure, and then two groups of patients were compared. A statistically significant difference was found between the distributions of the presence of silent micro-infarcts on DWI in terms of plaque characteristics (p 0.001). In the patients with normal DWI findings, the percentage of calcified plaques was 38.7%, while the percentages of hypoechoic plaques, plaques with low echogenicity, and ulcerated plaques were 91.3%, 85.7%, and 78.8%, respectively. The rates of calcified plaques and ulcerated plaques differed in the group of patients with silent micro-infarcts. The rate of silent micro-infarcts was 61.3% in the patients with calcified plaques, 8.7% in those with hypoechoic plaques, 14.3% in those with low-echogenicity plaques, and 21.2% in those with ulcerated plaques. The study found that carotid stents implanted in calcified and ulcerated plaques had a higher correlation with the presence of periprocedural asymptomatic ipsilateral DWI findings than those implanted in hypoechoic plaques and low-echogenicity plaques.

Computed Tomography Assessment of Coronary Atherosclerosis: From Threshold-Based Evaluation to Histologically Validated Plaque Quantification.

Arterial plaque rupture and thrombosis is the primary cause of major cardiovascular and neurovascular events. The identification of atherosclerosis, especially high-risk plaques, is therefore crucial to identify high-risk patients and to implement preventive therapies. Computed tomography angiography has the ability to visualize and characterize vascular plaques. The standard methods for plaque evaluation rely on the assessment of plaque burden, stenosis severity, the presence of positive remodeling, napkin ring sign, and spotty calcification, as well as Hounsfield Unit (HU)-based thresholding for plaque quantification; the latter with multiple shortcomings. Semiautomated threshold-based segmentation techniques with predefined HU ranges identify and quantify limited plaque characteristics, such as low attenuation, non-calcified, and calcified plaque components. Contrary to HU-based thresholds, histologically validated plaque characterization, and quantification, an emerging Artificial intelligence-based approach has the ability to differentiate specific tissue types based on a biological correlate, such as lipid-rich necrotic core and intraplaque hemorrhage that determine plaque vulnerability. In this article, we review the relevance of plaque characterization and quantification and discuss the benefits and limitations of the currently available plaque assessment and classification techniques.

Plasma Advanced Glycation End Products and Dicarbonyl Compounds Are Not Associated with Coronary Atherosclerosis in Athletes.

Coronary atherosclerosis is the leading cause of sudden death among athletes >35 yr old, but current cardiovascular risk prediction algorithms have not been validated for athletes. Advanced glycation end products (AGE) and dicarbonyl compounds have been associated with atherosclerosis and rupture-prone plaques in patients and ex vivo studies. The detection of AGE and dicarbonyl compounds might be a novel screening tool for high-risk coronary atherosclerosis in older athletes. Concentrations of three different AGE and the dicarbonyl compounds methylglyoxal, glyoxal, and 3-deoxyglucosone were measured in plasma with ultraperformance liquid chromatography tandem mass spectrometry in athletes from the Measuring Athletes' Risk of Cardiovascular Events 2 study cohort. Coronary plaques, plaque characteristics (calcified, noncalcified or mixed), and coronary artery calcium (CAC) scores were assessed with coronary computed tomography, and potential associations with AGE and dicarbonyl compounds were analyzed using linear and logistic regression. A total of 289 men were included (60 [quartiles 1-3 = 56-66] yr old, body mass index = 24.5 [22.9-26.6] kg·m -2 ), with a weekly exercise volume of 41 (25-57) MET-hours. Coronary plaques were detected in 241 participants (83%), with a dominant plaque type of calcified plaques in 42%, noncalcified plaques in 12% and mixed plaques in 21%. No AGE or dicarbonyl compounds were associated with total number of plaques or any of the plaque characteristics in adjusted analyses. Similarly, AGE and dicarbonyl compounds were not associated with CAC score. Concentrations of plasma AGE and dicarbonyl compounds do not predict the presence of coronary plaques, plaque characteristics or CAC scores, in middle-age and older athletes.

Convolutional neural networks on risk stratification of patients with suspected coronary artery disease undergoing coronary computed tomography angiography

To assess the prognostic value of convolutional neural networks (CNN) on coronary computed tomography angiography (CCTA) in comparison to conventional computed tomography (CT) reporting and clinical risk scores. 5468 patients who underwent CCTA with suspected coronary artery disease (CAD) were included. Primary endpoint was defined as a composite of all-cause death, myocardial infarction, unstable angina or late revascularization (> 90 days after CCTA). Early revascularization was additionally included as a training endpoint for the CNN algorithm. Cardiovascular risk stratification was based on Morise score and the extent of CAD (eoCAD) as assessed on CCTA. Semiautomatic post-processing was performed for vessel delineation and annotation of calcified and non-calcified plaque areas. Using a two-step training of a DenseNet-121 CNN the entire network was trained with the training endpoint, followed by training the feature layer with the primary endpoint. During a median follow-up of 7.2 years, the primary endpoint occurred in 334 patients. CNN showed an AUC of 0.631 ± 0.015 for prediction of the combined primary endpoint, while combining it with conventional CT and clinical risk scores showed an improvement of AUC from 0.646 ± 0.014 (based on eoCAD only) to 0.680 ± 0.015 (p < 0.0001) and from 0.619 ± 0.0149 (based on Morise Score only) to 0.6812 ± 0.0145 (p < 0.0001), respectively. In a stepwise model including all prediction methods, it was found an AUC of 0.680 ± 0.0148. CNN analysis showed to improve conventional CCTA-derived and clinical risk stratification when evaluating CCTA of patients with suspected CAD.

Nomogram for evaluating coronary revascularisation necessity based on multi-parameter coronary CT angiography

To build a nomogram model to improve the evaluation of revascularisation necessity using multi-parameter coronary computed tomography (CT) angiography (CCTA). In this retrospective study, 335 patients who underwent CCTA and required revascularisation within 1 month were selected and allocated to the revascularisation group; 208 patients who did not undergo revascularisation were allocated to the non-revascularisation group. CCTA parameters, including CCTA stenosis, plaque qualitative-quantitative characteristics, and fractional flow reserve derived from CT angiography (CT-FFR), for both groups were analysed and compared. Independent risk factors for evaluating revascularisation were obtained using univariate and multivariable regression analysis, after which multi-parameter models were built. Finally, a nomogram was created with these independent risk factors using the R programming language. Plaque analysis was performed successfully for 543 patients with 1,072 target plaques. The performance of the multi-parameter model (AUC 0.894, p<0.001) was significantly higher than that of models based on stenosis (AUC 0.804, p<0.001), plaque qualitative/quantitative characteristics (AUC 0.754/0.789, p<0.001), or CT-FFR (AUC 0.848, p<0.001) alone, to evaluate the necessity of revascularisation. The independent risk factors were CCTA stenosis (OR 1.004, p=0.04), positive remodelling (OR 2.474, p<0.001), total plaque volume (OR 1.001, p<0.001), non-calcified plaque volume proportion (OR 1.019, p<0.001), and CT-FFR (OR 0.001, p<0.001). Subsequently, a nomogram based on these factors was created. The multi-parameter CCTA model improved performance in evaluating revascularisation necessity. The nomogram based on these factors is shows promise in clinical settings.